These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 29939267)

  • 41. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
    Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
    Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and bla
    Tang C; Shen S; Yang W; Shi Q; Ding L; Han R; Hu F
    Int J Antimicrob Agents; 2024 Aug; 64(2):107228. PubMed ID: 38823494
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 46. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China.
    Shi Q; Yin D; Han R; Guo Y; Zheng Y; Wu S; Yang Y; Li S; Zhang R; Hu F
    Clin Infect Dis; 2020 Dec; 71(Suppl 4):S436-S439. PubMed ID: 33367577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.
    Antonelli A; Giani T; Di Pilato V; Riccobono E; Perriello G; Mencacci A; Rossolini GM
    J Antimicrob Chemother; 2019 Aug; 74(8):2464-2466. PubMed ID: 31318973
    [No Abstract]   [Full Text] [Related]  

  • 51. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
    Antinori E; Unali I; Bertoncelli A; Mazzariol A
    Clin Microbiol Infect; 2020 Jul; 26(7):946.e1-946.e3. PubMed ID: 32061796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
    Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
    J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.
    Shields RK; Nguyen MH; Hao B; Kline EG; Clancy CJ
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.
    Kristoffersson AN; Bissantz C; Okujava R; Haldimann A; Walter I; Shi T; Zampaloni C; Nielsen EI
    J Antimicrob Chemother; 2020 Feb; 75(2):400-408. PubMed ID: 31670804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.